Veracyte Inc - Understand $vcyt stock

$VCYT Market Cap: $2.593 Billion

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$399.6M

TTM

Gross Margin

68.76%

TTM

Net Earnings

-$54.04M

TTM

Current Assets

$321.1M

Q2 2024

Current Liabilities

$72.34M

Q2 2024

Current Ratio

443.89%

Q2 2024

Total Assets

$1.234B

Q2 2024

Total Liabilities

$101.8M

Q2 2024

Book Value

$1.133B

Q2 2024

Cash

$235.9M

Q2 2024

P/E

-47.99

Sep 18, 2024 EST

Free Cash Flow

$40.13M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Revenue	$361.1M	$296.5M	$219.5M	$117.5M	$120.4M	$92.01M	$71.95M	$65.09M	$49.50M	$38.19M	$21.88M	$11.63M	$2.645M
YoY Change	21.76%	35.09%	86.85%	-2.4%	30.82%	27.87%	10.55%	31.48%	29.62%	74.51%	88.2%	339.62%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Revenue	$361.1M	$296.5M	$219.5M	$117.5M	$120.4M	$92.01M	$71.95M	$65.09M	$49.50M	$38.19M	$21.88M	$11.63M	$2.645M
Cost Of Revenue	$112.9M	$101.6M	$74.40M	$41.50M	$36.08M	$33.08M	$28.20M	$25.46M	$21.50M	$16.61M	$12.61M	$7.584M	$2.925M
Gross Profit	$248.1M	$195.0M	$145.1M	$76.00M	$84.29M	$58.93M	$43.76M	$39.62M	$28.01M	$21.58M	$9.277M	$4.044M	-$280.0K
Gross Profit Margin	68.73%	65.74%	66.11%	64.69%	70.03%	64.05%	60.81%	60.88%	56.57%	56.52%	42.39%	34.78%	-10.59%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Selling, General & Admin	$187.7M	$174.1M	$181.2M	$89.12M	$82.72M	$65.28M	$55.35M	$52.04M	$47.88M	$40.79M	$24.64M	$16.37M	$8.306M
YoY Change	7.84%	-3.93%	103.32%	7.73%	26.72%	17.94%	6.37%	8.69%	17.38%	65.53%	50.57%	97.03%
% of Gross Profit	75.65%	89.29%	124.86%	117.26%	98.14%	110.77%	126.49%	131.33%	170.95%	188.96%	265.6%	404.67%
Research & Development	$57.31M	$40.60M	$29.84M	$17.20M	$14.85M	$14.82M	$13.88M	$15.32M	$12.80M	$9.804M	$7.810M	$6.608M	$6.680M
YoY Change	41.13%	36.06%	73.47%	15.84%	0.21%	6.76%	-9.42%	19.76%	30.52%	25.53%	18.19%	-1.08%
% of Gross Profit	23.09%	20.83%	20.57%	22.64%	17.62%	25.15%	31.72%	38.67%	45.69%	45.42%	84.19%	163.4%
Depreciation & Amortization	$27.19M	$25.93M	$19.59M	$7.944M	$4.117M	$3.920M	$3.841M	$3.511M	$2.254M	$1.200M	$999.0K	$706.0K	$611.0K
YoY Change	4.86%	32.33%	146.64%	92.96%	5.03%	2.06%	9.4%	55.77%	87.83%	20.12%	41.5%	15.55%
% of Gross Profit	10.96%	13.3%	13.5%	10.45%	4.88%	6.65%	8.78%	8.86%	8.05%	5.56%	10.77%	17.46%
Operating Expenses	$245.0M	$214.7M	$211.0M	$106.3M	$97.57M	$114.2M	$98.49M	$93.89M	$82.97M	$67.20M	$45.06M	$30.56M	$17.91M
YoY Change	14.13%	1.73%	98.49%	8.97%	-14.59%	15.99%	4.9%	13.16%	23.47%	49.14%	47.45%	70.6%
Operating Profit	-$85.80M	-$41.08M	-$81.90M	-$35.39M	-$15.13M	-$22.23M	-$26.54M	-$28.80M	-$33.47M	-$29.01M	-$23.17M	-$18.93M	-$15.27M
YoY Change	108.84%	-49.84%	131.44%	133.95%	-31.96%	-16.22%	-7.86%	-13.93%	15.38%	25.17%	22.42%	23.99%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Interest Expense	$8.052M	$1.971M	-$1.187M	$229.0K	$677.0K	$1.963M	$4.941M	$2.757M	$378.0K	$439.0K	$233.0K	$0.00	$0.00
YoY Change	308.52%	-266.05%	-618.34%	-66.17%	-65.51%	-60.27%	79.22%	629.37%	-13.9%	88.41%
% of Operating Profit
Other Income/Expense, Net	$9.183M	$4.654M	$254.0K	$480.0K	$2.528M	$1.197M	$476.0K	$202.0K	$140.0K	$72.00K	-$2.179M	$278.0K	$819.0K
YoY Change	97.31%	1732.28%	-47.08%	-81.01%	111.19%	151.47%	135.64%	44.29%	94.44%	-103.3%	-883.81%	-66.06%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Pretax Income	-$76.61M	-$36.43M	-$81.65M	-$34.91M	-$12.60M	-$23.00M	-$31.00M	-$31.40M	-$33.70M	-$29.40M	-$25.60M	-$18.60M	-$14.40M
YoY Change	110.32%	-55.39%	133.89%	177.08%	-45.22%	-25.81%	-1.27%	-6.82%	14.63%	14.84%	37.63%	29.17%
Income Tax	-$2.208M	$133.0K	-$6.086M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$74.40M	-$36.56M	-$75.56M	-$34.91M	-$12.60M	-$23.00M	-$31.00M	-$31.40M	-$33.70M	-$29.40M	-$25.60M	-$18.60M	-$14.40M
YoY Change	103.51%	-51.62%	116.46%	177.08%	-45.22%	-25.81%	-1.27%	-6.82%	14.63%	14.84%	37.63%	29.17%
Net Earnings / Revenue	-20.61%	-12.33%	-34.42%	-29.71%	-10.47%	-25.0%	-43.08%	-48.24%	-68.08%	-76.98%	-116.98%	-159.96%	-544.42%
Basic Earnings Per Share	-$1.02	-$0.51	-$1.11	-$0.66	-$0.27
Diluted Earnings Per Share	-$1.02	-$0.51	-$1.11	-$0.66	-$0.27	-$621.6K	-$914.5K	-$1.090M	-$1.296M	-$1.361M	-$1.225M	-$898.6K	-$695.7K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Cash & Short-Term Investments	$216.5M	$178.9M	$173.2M	$349.4M	$159.3M	$78.00M	$33.90M	$59.20M	$39.10M	$35.00M	$71.20M	$14.00M	$7.600M
YoY Change	21.02%	3.27%	-50.43%	119.33%	104.23%	130.09%	-42.74%	51.41%	11.71%	-50.84%	408.57%	84.21%
Cash & Equivalents	$216.5M	$154.2M	$173.2M	$349.4M	$159.3M	$78.00M	$33.90M	$59.20M	$39.10M	$35.00M	$71.20M	$14.00M	$7.600M
Short-Term Investments	$0.00	$24.61M
Other Short-Term Assets	$12.66M	$11.47M	$17.22M	$3.200M	$2.200M	$2.400M	$2.000M	$2.200M	$1.500M	$1.600M	$1.500M	$800.0K	$500.0K
YoY Change	10.39%	-33.39%	438.09%	45.45%	-8.33%	20.0%	-9.09%	46.67%	-6.25%	6.67%	87.5%	60.0%
Inventory	$16.13M	$14.29M	$11.23M	$4.700M	$6.800M	$3.400M	$5.300M	$3.500M	$3.800M	$3.700M	$2.600M	$1.100M	$300.0K
Prepaid Expenses
Receivables	$40.38M	$44.02M	$41.46M	$18.50M	$19.30M	$13.20M	$12.70M	$8.800M	$3.500M	$3.100M	$1.100M	$600.0K	$200.0K
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$285.6M	$248.6M	$243.1M	$375.7M	$187.7M	$97.00M	$53.90M	$73.60M	$47.90M	$43.30M	$76.40M	$16.40M	$8.600M
YoY Change	14.88%	2.28%	-35.29%	100.16%	93.51%	79.96%	-26.77%	53.65%	10.62%	-43.32%	365.85%	90.7%
Property, Plant & Equipment	$30.86M	$30.86M	$31.14M	$16.80M	$17.70M	$8.900M	$9.700M	$11.50M	$10.30M	$4.200M	$3.000M	$2.400M	$1.700M
YoY Change	0.0%	-0.9%	85.36%	-5.08%	98.88%	-8.25%	-15.65%	11.65%	145.24%	40.0%	25.0%	41.18%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$6.847M	$6.167M	$2.947M	$2.000M	$2.000M	$1.700M	$900.0K	$700.0K	$800.0K	$300.0K	$300.0K	$200.0K	$200.0K
YoY Change	11.03%	109.26%	47.35%	0.0%	17.65%	88.89%	28.57%	-12.5%	166.67%	0.0%	50.0%	0.0%
Total Long-Term Assets	$829.3M	$907.8M	$944.7M	$81.50M	$87.50M	$23.60M	$24.80M	$27.40M	$27.30M	$21.50M	$3.200M	$2.700M	$1.900M
YoY Change	-8.65%	-3.91%	1059.17%	-6.86%	270.76%	-4.84%	-9.49%	0.37%	26.98%	571.88%	18.52%	42.11%
Total Assets	$1.115B	$1.156B	$1.188B	$457.2M	$275.2M	$120.6M	$78.70M	$101.0M	$75.20M	$64.80M	$79.60M	$19.10M	$10.50M
YoY Change
Accounts Payable	$12.94M	$11.91M	$12.36M	$3.100M	$2.300M	$2.500M	$3.900M	$2.400M	$5.100M	$7.400M	$5.300M	$1.900M	$600.0K
YoY Change	8.66%	-3.63%	298.71%	34.78%	-8.0%	-35.9%	62.5%	-52.94%	-31.08%	39.62%	178.95%	216.67%
Accrued Expenses	$43.53M	$41.84M	$43.11M	$13.30M	$15.10M	$9.200M	$8.200M	$9.100M	$8.700M	$7.900M	$7.600M	$4.000M	$1.300M
YoY Change	4.03%	-2.93%	224.1%	-11.92%	64.13%	12.2%	-9.89%	4.6%	10.13%	3.95%	90.0%	207.69%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00	$1.127M		$0.00	$1.400M
YoY Change		-100.0%			-100.0%
Total Short-Term Liabilities	$61.24M	$62.61M	$64.15M	$16.80M	$17.50M	$13.10M	$12.00M	$11.50M	$14.70M	$17.10M	$15.40M	$9.000M	$1.900M
YoY Change	-2.19%	-2.4%	281.85%	-4.0%	33.59%	9.17%	4.35%	-21.77%	-14.04%	11.04%	71.11%	373.68%
Long-Term Debt	$100.0K	$400.0K	$600.0K	$800.0K	$700.0K	$23.90M	$25.20M	$25.50M	$5.000M	$4.900M	$4.900M	$0.00	$0.00
YoY Change	-75.0%	-33.33%	-25.0%	14.29%	-97.07%	-5.16%	-1.18%	410.0%	2.04%	0.0%
Other Long-Term Liabilities	$8.829M	$13.68M	$20.97M	$18.30M	$17.60M	$3.900M	$4.200M	$4.400M	$4.300M	$1.100M	$2.900M	$5.200M	$0.00
YoY Change	-35.45%	-34.77%	14.58%	3.98%	351.28%	-7.14%	-4.55%	2.33%	290.91%	-62.07%	-44.23%
Total Long-Term Liabilities	$8.829M	$14.08M	$21.57M	$19.10M	$18.30M	$27.80M	$29.40M	$29.90M	$9.300M	$6.000M	$7.800M	$5.200M	$0.00
YoY Change	-37.28%	-34.73%	12.92%	4.37%	-34.17%	-5.44%	-1.67%	221.51%	55.0%	-23.08%	50.0%
Total Liabilities	$70.80M	$81.22M	$91.31M	$35.90M	$35.80M	$40.90M	$41.40M	$41.50M	$24.00M	$23.50M	$23.20M	$14.20M	$1.900M
YoY Change	-12.83%	-11.05%	154.35%	0.28%	-12.47%	-1.21%	-0.24%	72.92%	2.13%	1.29%	63.38%	647.37%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019
Basic Shares Outstanding	72.64M shares	71.55M shares	67.89M shares	53.24M shares	46.14M shares
Diluted Shares Outstanding	72.64M shares	71.55M shares	67.89M shares	53.24M shares	46.14M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Dividends

Stock Price

Market Cap: $2.5932 Billion

About Veracyte Inc

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The company is headquartered in South San Francisco, California and currently employs 815 full-time employees. The company went IPO on 2013-10-30. The firm enables clinicians with insights they need to guide and assure patients. The firm offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. Its products consist of the Prosigna breast cancer assay, the nCounter Analysis System, related diagnostic kits, and services. In the United States, it offers laboratory developed tests (LDTs), through its CLIA labs in South San Francisco and San Diego, California, supported by its cytopathology know-how in Austin, Texas. The firm also offers whole-genome MRD platform that enable it in early cancer diagnosis and risk assessment.

Industry: Services-Medical Laboratories Peers: CHINOOK THERAPEUTICS, INC. Akero Therapeutics Inc Celldex Therapeutics Inc Catalyst Pharmaceuticals Inc Deciphera Pharmaceuticals, Inc. Dynavax Technologies Corp Ligand Pharmaceuticals Inc Syndax Pharmaceuticals Inc SpringWorks Therapeutics Inc